CING Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 113605 min ago

@ $1.240

Wydano: 13 vas. 2024 @ 16:47

Zwrot: -16.13%

Poprzedni sygnał: vas. 9 - 17:37

Poprzedni sygnał: Kupno

Zwrot: 7.63 %

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder...

Stats
Dzisiejszy wolumen	61 077.00
Średni wolumen	272 462
Kapitalizacja rynkowa	4.14M
EPS	$-5.94 ( 2024-04-05 )
Następna data zysków	( $-2.20 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00600 (0.58%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Werth Peter J.	Buy	694 096	Common Stock
2024-04-11	Werth Peter J.	Buy	341 912	Common Stock
2024-04-11	Werth Peter J.	Sell	694 096	Pre-Funded Warrant (right to buy)
2024-04-11	Werth Peter J.	Sell	341 912	Pre-Funded Warrant (right to buy)
2024-03-29	Silva Raul R.	Buy	1 000	Stock Option (right to Buy)

INSIDER POWER
77.31
Last 96 transactions
Buy: 11 671 641 \| Sell: 1 062 040

Cingulate Inc. Korelacja

10 Najbardziej pozytywne korelacje
ADXN	0.805

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cingulate Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-582 918 (0.00 %)
EPS:	$-26.00

FY	2023
Przychody:	$0
Zysk brutto:	$-582 918 (0.00 %)
EPS:	$-26.00

FY	2022
Przychody:	$0
Zysk brutto:	$-621 993 (0.00 %)
EPS:	$-31.57

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.831

Financial Reports:

No articles found.

Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.